Program
PF-08046044
A development code. Also written as “PF-08046044/SGN-35C”.
In Pfizer's pipeline, CD30-directed antibody TOPO1 drug conjugate
. Its studies are mostly in Hodgkin Disease, led by Pfizer.
Furthest: phase 1, since Feb 2, 20241 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 10 open or running | phase 1since Feb 2, 2024 | Feb 2, 2024 | none ahead |
- Named in Pfizer’s own pipeline as
PF-08046044
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 2, 2024First study: phase 1 study in Hodgkin DiseaseFirst studyNCT06254495 · 58 enrolled · United States, Denmark, France and more
TargetBeta
“CD30-directed antibody TOPO1 drug conjugate”the company's pipeline, read by Claude · source
Other programs on TNFRSF8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Brentuximab Vedotinrule | Pfizer | phase 4 | 37 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06254495Hodgkin Disease · United States, Denmark, France and more | 1 | Terminated | Apr 13, 2026 | 58 |
How it is read
Names in the registry
- “PF-08046044/SGN-35C”, 1 entry
Codes read as this program: PF08046044.
Conditions, from the studies’ own filings
- Hodgkin Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.